Question-and-Answer Session
Operator
(Operator Instructions) The first question comes from the line of Matt Dolan – Roth Capital.
Matt Dolan – Roth Capital
On the Hospira transition and specifically looking at the Critical care line that number came in still pretty strong despite the transition for a month and a half. Maybe you could break out that $7.4 million as to when those sales came through. Then touch on the rest of the business in terms of how we really derive an underlying growth figure for the quarter?
Scott Lamb
Well we completed the transaction on August 31 so as of September 1 we started recognizing sales for the Critical care product line. Those sales would have been what Hospira previously would have recognized on their sales to the end customer. So we have a full month of sales for Critical care.
Matt Dolan – Roth Capital
At the end user price?
Scott Lamb
At the end user price. That is correct.
Matt Dolan – Roth Capital
Looking at the rest of the business it looks like CLAVE was flat again sequentially although up pretty nicely year-over-year. Maybe just walk us through, especially as we look into Q4 is it going to require a double digit growth both sequentially and year-over-year and clearly the transition will help but what are you hearing generally that gives you confidence some of the inventory issues we saw earlier in the year aren’t going to come back and you will return to some normalized growth rate outside of obviously the Critical care piece that is in the middle of the transition?
Dr. George Lopez
Outside of Critical care, we still believe that CLAVE for example will continue in the foreseeable future to grow in the mid to high single digits. As we look at our sell through data it is up where we expect it to be and it is doing very well. It is still going very strong. This was mainly due to Hospira’s project fuel and as we announced in our second quarter conference call we expect Hospira’s CLAVE sales to be flat to slightly down for the second half of this year. Sell through is still going very strong.
Matt Dolan – Roth Capital
One thing you didn’t mention in the prepared remarks is Premier. Any updates for us there? Any traction that you have seen and what are you expecting to be able to bring or sell through ICU products in 2010 because of that relationship?
- To read the full transcript on Seeking Alpha, click here »
